ConXn recombinant human relaxin H2: CNCT began Phase II testing of safety and efficacy

Connective Therapeutics Inc. (CNCT), Palo Alto, Calif. Product: ConXn recombinant human relaxin H2 Indication: Scleroderma, a hardening of skin and internal organs Status: CNCT began Phase II testin...